New Insights into the Mechanism and Treatment of Idiopathic Ventricular Arrhythmias

Why do ventricular arrhythmias occur in perfectly healthy people with a seemingly normal and potent heart? This question lies at the core of this thesis. In the general population these so-called idiopathic ventricular arrhythmias (IVAs) are common and present in varying degrees of severity. The subgroup that accounts for the largest share of IVAs are the outflow tract IVAs, named after their referred location. They can be highly symptomatic with complaints ranging from palpitations to hemodynamic instability and can cause tachycardia-induced cardiomyopathy. Fortunately, however, they usually have a good prognosis. For the past decades, it has been generally accepted that the underlying mechanism of this arrhythmia is triggered activity. Curiously enough, other than providing a mechanistic classification, this categorization does not elucidate the actual underlying etiology, the distinctive localized nature or many other key characteristics of this arrhythmia. In this thesis, we aim to clarify these aspects in order to provide new insights into the mechanism and treatment of IVAs

Clinical outcome of ablation for long-standing persistent atrial fibrillation with or without defragmentation

Objective To assess the outcome and associated risks of atrial defragmentation for the treatment of long-standing persistent atrial fibrillation (LSP-AF). Methods Thirty-seven consecutive patients (60.4±7.3 years; 28 male) suffering from LSP-AF who underwent pulmonary vein isolation (PVI) and linear ablation were compared. All patients were treated with the Stereotaxis magnetic navigation system (MNS). Two groups were distinguished: patients with (n =20) and without (n =17) defragmentation. The primary endpoint of the study was freedom of AF after 12 months. Secondary endpoints were AF termination, procedure time, fluoroscopy time and procedural complications. Complications were divided into two groups: Major (infarction, stroke, major bleeding and tamponade) and minor (fever, pericarditis and inguinal haematoma). Results No difference was seen in freedom of AF between the defragmentation and the non-defragmentation group (56.2 % vs. 40.0%, P=0.344). Procedure times in the defragmentation group were longer; no differences in fluoroscopy times were observed. No major complications occurred. A higher number of minor complications occurred in the defragmentation group (45.0 % vs. 5.9 %, P=0.009). Mean hospital stay was comparable (4.7±2.2 vs. 3.4±0.8 days, P=0.06). Conclusion Our study suggests that complete defragmentation using MNS is associated with a higher number of minor complications and longer procedure times and thus compromises efficiency without improving efficacy

Ventricular tachycardia in ischemic cardiomyopathy; a combined endo-epicardial ablation as the first procedure versus a stepwise approach (EPILOGUE) - study protocol for a randomized controlled trial

Background: The role of epicardial substrate ablation of ventricular tachycardia (VT) as a first-line approach in patients with ischemic heart disease is not clearly defined. Epicardial ablation as a first-line option is standard for patients with nonischemic dilated cardiomyopathy and arrhythmogenic right ventricular cardiomyopathy. Several nonrandomized studies, including studies on patients with ischemic heart disease, have shown that epicardial VT ablation improves outcome but this approach was often used after a failed endocardial approach. The aim of this study is to determine whether a combined endo-epicardial scar homogenization as a first-line approach will improve the outcome of VT ablation. Methods/Design: The EPILOGUE study is a multicenter, two-armed, nonblinded, randomized controlled trial. Patients with ischemic heart disease who are referred for VT ablation will be randomly assigned to combined endo-epicardial scar homogenization or endocardial scar homogenization only (control group). The primary outcome is recurrence of sustained VT during a 2-year follow-up. Secondary outcomes include procedural success and safety. Discussion: This study is the first randomized trial that evaluates the role of a combined endo-epicardial scar homogenization versus endocardial scar homogenization for the treatment of ischemic scar-related VT. Trial registration:NL4816807814v0